← All Signals

🏥 FDA: Radnostix — Class III

healthcareneutralSource: FDA
70%Confidence
0Views
FDASource
2026-04-07Date

Summary

Radnostix's Class III recall for failed capsule specifications in a diagnostic kit poses lower health risks but reflects manufacturing inconsistencies. This may lead to minor operational disruptions and increased quality monitoring costs for the company.

Actionable: Assess Radnostix's manufacturing processes to ensure compliance with diagnostic kit standards.

AI Confidence: 70%

Data Points

firmRadnostix
classificationClass III
statusOngoing
distributionNationwide in the US, including Puerto Rico
productGelatin Capsule Pack for use with the Sodium Iodide I-131 Kit (containing 5 empty capsules and 5 Dibasic Sodium Phosphate Capsules 300 mg, Internation

Get Signals Instantly

Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.

Subscribe Now